Email list hosting service & mailing list manager


Re: final technical reports for NIH projects under competitive renewal Nolan, Linda J. 17 Sep 2008 13:10 EST

When a competing continuation is awarded, NIH automatically terminates
the no-cost extension (if one exists), so the subcontracts have to be
terminated also.

-----Original Message-----
From: Research Administration List [mailto:xxxxxx@hrinet.org] On
Behalf Of Burnside, Sherry
Sent: Wednesday, September 17, 2008 1:58 PM
To: xxxxxx@hrinet.org
Subject: Re: [RESADM-L] final technical reports for NIH projects under
competitive renewal

Folks let me describe a slightly different twist and ask a question.  We
have a subcontract on a project that is a continuation that has been
funded early!  The previous segment now has a new stop date 5 months
early so funds remain.  The new funds have the same grant number.  We
had no warning that this was about to happen.

How would you handle a new subcontract to allow spending of the previous
funds?

THANKS ALL!

-----Original Message-----
From: Research Administration List [mailto:xxxxxx@hrinet.org] On
Behalf Of Donahue, Sherie (LLU)
Sent: Wednesday, September 17, 2008 10:50 AM
To: xxxxxx@hrinet.org
Subject: Re: [RESADM-L] final technical reports for NIH projects under
competitive renewal

In a similar situation, one of our PI's was directed by his NIH program
director not to close out the project while waiting for the new grant to
come through. I think that it has something to do with how many years of
continuous funding and how that looks to reviewers.

Sherie Donahue, MS
Office of the Vice Chancellor for Research Affairs
Loma Linda University
Loma Linda, CA 92350
909/558-3928 or 909/558-1000, x83911
909/558-0244 (fax)

-----Original Message-----
From: Research Administration List [mailto:xxxxxx@hrinet.org] On
Behalf Of Aull, Robert Matthew
Sent: Wednesday, September 17, 2008 8:06 AM
To: xxxxxx@hrinet.org
Subject: Re: [RESADM-L] final technical reports for NIH projects under
competitive renewal

Zoya,

My experience has been that NIH requires that projects remain open in
order to be competitively renewed, hence the need for a no-cost
extension while the competing proposal is being reviewed.

A truly final technical report and/or grant closeout would not be
appropriate so long the investigator has a pending application with the
same grant number (through the -A2 designation).

Robert Aull
Indiana University School of Medicine

-----Original Message-----
From: Research Administration List [mailto:xxxxxx@hrinet.org] On
Behalf Of Zoya Hamilton
Sent: Wednesday, September 17, 2008 10:36 AM
To: xxxxxx@hrinet.org
Subject: [RESADM-L] final technical reports for NIH projects under
competitive renewal

Colleagues,

Do you agree that final technical reports should be submitted for the
NIH grants that ended before the application for a competitive renewal
has been reviewed? I cannot think of a reason how submitting a final
progress report can be detrimental to the project's likelihood to be
funded in the new cycle. Has anyone experienced any problems with
closing grants and then getting a renewal funded? I am asking because
some PIs are not comfortable with the idea of closing their grants while
they are hoping that their competitive renewal to be funded.

Thanks so much for your inputs.

Zoya

--
Zoya Hamilton, CRA
Sr. Associate Director, Research Administration
Office of the Vice Provost
Tufts University
Tel (617) 636-6709
Fax (617) 636-2917
http://www.tufts.edu/central/

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================

The information contained in this message and any attachments is
intended only for the use of the individual or entity to which it is
addressed, and may contain information that is PRIVILEGED, CONFIDENTIAL,
and exempt from disclosure under applicable law.  If you are not the
intended recipient, you are prohibited from copying, distributing, or
using the information.  Please contact the sender immediately by return
e-mail and delete the original message from your system.

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================

This transmission may be confidential or protected from disclosure and is only for review and use by the intended recipient. Access by anyone else is unauthorized. Any unauthorized reader is hereby notified that any review, use, dissemination, disclosure or copying of this information, or any act or omission taken in reliance on it, is prohibited and may be unlawful. If you received this transmission in error, please notify the sender immediately. Thank you.

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================